Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

BioInvent International AB (BINV) NPV

Sell:1.75 SEK Buy:1.77 SEK Change: 0.036 SEK (2.01%)
Market closed |  Prices as at close on 11 August 2020 | Switch to live prices |
Sell:1.75 SEK
Buy:1.77 SEK
Change: 0.036 SEK (2.01%)
Market closed |  Prices as at close on 11 August 2020 | Switch to live prices |
Sell:1.75 SEK
Buy:1.77 SEK
Change: 0.036 SEK (2.01%)
Market closed |  Prices as at close on 11 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioInvent International AB (BioInvent) is a Sweden-based biopharmaceutical company. The Company is engaged in the research and development of antibody-based drugs for the treatment of diseases, such as thrombosis, cancer and acute coronary artery disease. Its product range includes human antibodies, such as TB-402, TB-403, BI-204 and BI-505, as well as licenses. BioInvent is active in the co-development of intellectual property through strategic product alliances with ThromboGenics Ltd and Roche Group. It has has entered into several product partnerships with Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. As of December 31, 2011, the Company had one wholly owned subsidiary BioInvent Finans AB, engaged in the administration of warrants issued by the Company. As of December 31, 2011, the Company’s largest shareholder was JP Morgan Bank. In May 2014, the Company sold back all its rights to product candidate ADC-1013 to its former partner Alligator Bioscience AB.

Contact details

Ideon Science Park
223 70
+46 (46) 2868550

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.71 billion SEK
Shares in issue:
510.73 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Leonard Kruimer
    Independent Chairman of the Board
  • Martin Welschof
    President, Chief Executive Officer
  • Stefan Ericsson
    Chief Financial Officer
  • Kristoffer Rudenholm Hansson
    Senior Vice President, Technical Operations
  • Bjorn Frendeus
    Chief Scientific Officer
  • Andres McAllister
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.